Table 2 Demographic and clinical data of study participants without or with MACE
|  | NO MACE (n = 120) | MACE (n = 81) | p value |
|---|---|---|---|
Men/female, n | 85:35 | 65:16 | 0.13 |
Age, years ± SD | 74.5 ± 9.3 | 75.5 ± 8.3 | 0.44 |
Diabetes duration, years ± SD | 11.4 ± 0.9 | 11.4 ± 0.8 | 0.92 |
BMI, Kg/m2 ± SD | 26.7 ± 0.6 | 26.8 ± 0.7 | 0.22 |
Smoking (current), n (%) | 47 (39.2) | 56 (69.1) |  < 0.01 |
Smoking (former), n (%) | 50 (41.7) | 18 (22.2) |  < 0.01 |
Never smoked, n (%) | 24 (20.0) | 7 (8.6) | 0.03 |
Hypertension, n (%) | 85 (70.8) | 61 (75.3) | 0.48 |
Hypercholesterolemia, n (%) | 68 (56.7) | 41 (50.6) | 0.40 |
CAD, n (%) | 54 (45.0) | 39 (48.1) | 0.66 |
CVD, n (%) | 58 (48.3) | 41 (50.6) | 0.75 |
Oral antidiabetic agents, n (%) | 52 (43.3) | 37 (45.7) | 0.74 |
Insulin, n (%) | 86 (71.7) | 61 (75.3) | 0.57 |
ABI, ± SD | 0.6 ± 0.1 | 0.6 ± 0.1 | 0.75 |
Rutherford II-4, n (%) | 68 (56.7) | 41 (50.6) | 0.40 |
Rutherford III-5, n (%) | 52 (43.3) | 40 (49.4) | 0.40 |
WIfI010, n (%) | 32 (26.7) | 29 (35.8) | 0.17 |
WIfI020, n (%) | 35 (29.2) | 16 (19.8) | 0.13 |
WIfI110, n (%) | 26 (21.7) | 23 (28.4) | 0.27 |
WIfI120, n (%) | 27 (22.5) | 13 (16.0) | 0.26 |
HbA1c, % ± SD | 8.9 ± 0.7 | 8.8 ± 0.7 | 0.30 |
FBG, mg/dL ± SD | 128.0 ± 10.0 | 127.8 ± 9.1 | 0.89 |
Total cholesterol, mg/dL ± SD | 219.4 ± 21.5 | 218.1 ± 23.6 | 0.67 |
LDL cholesterol, mg/dL ± SD | 112.0 ± 15.4 | 113.0 ± 15.6 | 0.70 |
Triglycerides, mg/dL ± SD | 171.1 ± 8.3 | 174.5 ± 8.3 |  < 0.01 |
eGFR, mL/min/1.73m2 ± SD | 72.3 ± 10.5 | 73.0 ± 10.6 | 0.67 |
HMGB-1, ng/mL ± SD | 4.9 ± 2.6 | 7.5 ± 1.9 |  < 0.01 |